Table 3.
Case and control definitions for COH studies
| Author | Country | Year | No. of cases | No. of controls | BRCA1 only | BRCA2 only | BRCA1 and 2 | Either | % Ashkenazi Jewish for BRCA+ pts |
|---|---|---|---|---|---|---|---|---|---|
| Oktay | USA | 2010 | 12 | 68 | 12 | “A large population of people in our geographic area are of Ashkenazi Jewish origin” | |||
| Shapira | Israel | 2015 | 62 | 62 | 62 | Yes. “In the present study, a high local prevalence of BRCA1/2+ (2.5% among Ashkenazi Jews), combined with an easy access to and increased demand for IVF among carriers, allowed us to evaluate a relatively large group of both non-cancer- and cancer-affected BRCA mutation carriers, undergoing IVF treatment for PGD and fertility preservation.” | |||
| Lambertini | Belgium | 2018 | 10 | 19 | 5 | 5 | Not reported | ||
| Derks-Smeets | Netherlands, Belgium | 2017 | 43 | 175 | 20 | 23 | Not reported | ||
| Gunnala (cohort 1) | USA | 2019 | 38 | 53 + 85 | 31 | 18 | 4 | Data not reported, but author communication indicated the geographic region had “significant percentage” Jewish patients | |
| Gunnala (cohort 2) | USA | 2019 | 19 | 600 | See Gunnala above | ||||
| Turan | Turkey/USA | 2018 | 21 | 97 | 21 | Not reported | |||
| Total | 205 | 1159 | 56 | 46 | 4 | 95 | |||
| MIN | 10 | 19 | 5 | 5 | 4 | 12 | |||
| MAX | 62 | 600 | 31 | 23 | 4 | 62 |